alloxan has been researched along with liraglutide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iemoto, K; Kudo, M; Minami, K; Seino, S; Takahashi, H; Tamura, K | 1 |
| Kong, SM; Tang, RQ; Tian, JY; Wu, S; Yang, HK; Ye, F; Zhang, P; Zhang, XL; Zhang, Y; Zhou, Y | 1 |
2 other study(ies) available for alloxan and liraglutide
| Article | Year |
|---|---|
Liraglutide improves pancreatic Beta cell mass and function in alloxan-induced diabetic mice.
Topics: Alloxan; Animals; Apoptosis; Blood Glucose; Cell Proliferation; Cell Size; Diabetes Mellitus, Experimental; Energy Metabolism; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liraglutide; Mice; Mice, Transgenic; Oxidative Stress | 2015 |
[The effects of compound CX09040 on the inhibition of PTP1B and protection of pancreatic β cells].
Topics: Alloxan; Animals; Benzoates; Biological Assay; Disease Models, Animal; Glucose; Glucose Tolerance Test; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Liraglutide; Mice; Mice, Inbred ICR; Molecular Weight; Pancreas; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Signal Transduction | 2015 |